Notfälle
Blutspende
Karriere
Presse
Forschung
Lehre
Patienten
Zuweiser

Publikationen

Stand: 25.03.2017

 

2017

Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017 Mar 5. pii: S0167-8140(17)30038-5. doi: 

Medenwald D, Vordermark D, Dietzel CT. Cancer mortality in former East and West Germany: a story of unification? BMC Cancer. 2017 Feb 2;17(1):94. doi: 10.1186/s12885-017-3086-y.

Simmermacher S, Vordermark D, Kegel T, Strauss C. Malignization of vestibular schwannoma 13 years after radiation therapy. HNO. 2017 Jan 5. doi: 10.1007/s00106-016-0321-9. [Epub ahead of print]

 

Polat B, Kaiser P, Wohlleben G, Gehrke T, Scherzad A, Scheich M, Malzahn U, Fischer T, Vordermark D, Flentje M. Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer. 2017 Jan 3;17(1):6. 

 

2016

Keßler J, Rot S, Bache M, Kappler M, Würl P, Vordermark D, Taubert H, Greither T. miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome. Oncol Lett. 2016 Dec;12(6):5281-5288. doi: 10.3892/ol.2016.5320.

Ostheimer C, Hübsch P, Janich M, Gerlach R, Vordermark D. Dosimetric comparison of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in total scalp irradiation: a single institutional experience. Radiat Oncol J. 2016 Dec;34(4):313-321. 

Ostheimer C, Schweyer F, Reese T, Bache M, Vordermark D. The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncol Lett 12: 3449-3456, 2016.

Renner SK, Vordermark D, Beckmann MW. Aktuelle interdisziplinäre Aspekte zur primären Therapie des Zervixkarzinoms. Best Practice Onkologie 2016, 11(5):44-52.

Höcht S, Vordermark D. Adjuvante Strahlentherapie beim Endometriumkarzinom. Onkologe 2016. DOI 10.1007/s00761-016-0148-8.

Vordermark. Radiotherapy of Cervical Cancer. Oncol Res Treat. 2016;39(9):516-20. doi: 10.1159/000448902. Epub 2016 Aug 18. 

Vordermark D, Pelz T. Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today? J Clin Oncol. 2016 Aug 20;34(24):2939-40. doi: 10.1200/JCO.2015.65.8286. Epub 2016 May 2. 

Kuhnt T, Stang A, Wienke A, Vordermark D, Schweyen R, Hey J. Potential risk factors for jaw osteoradionecrosis after radiotherapy for head and neck cancer. Radiat Oncol. 2016 Jul 30;11:101. doi: 10.1186/s13014-016-0679-6.

Gnanapragassam VS, Bork K, Galuska CE, Galuska SP, Glanz D, Nagasundaram M, Bache M, Vordermark D, Kohla G, Kannicht C, Schauer R, Horstkorte R. Correction: Sialic Acid Metabolic Engineering: A Potential Strategy for the Neuroblastoma Therapy. PLoS One. 2016 Apr 19;11(4):e0154289. doi: 10.1371/journal.pone.0154289. eCollection 2016. 

Kühnöl J, Kühnöl C, Vordermark D. Radiotherapy of brain metastases from breastcancer: Treatment results and prognostic factors. Oncology Lett, Mar 2016 [in press]. 

Vordermark D, Horsman MR. Hypoxia as a Biomarker and for Personalized Radiation Oncology. Recent Results Cancer Res. 2016;198:123-42. doi:10.1007/978-3-662-49651-0_6. 

Steineck G, Schmidt H, Alevronta E, Sjöberg F, Bull CM, Vordermark D.Toward Restored Bowel Health in Rectal Cancer Survivors. Semin Radiat Oncol. 2016 Jul;26(3):236-50. doi: 10.1016/j.semradonc.2016.03.002. Epub 2016 Mar 18. 

Kappler M, Pabst U, Rot S, Taubert H, Wichmann H, Schubert J, Bache M, Weinholdt C, Immel UD, Grosse I, Vordermark D, Eckert AW. Normoxic accumulation of HIF1α is associated with glutaminolysis. Clin Oral Investig. 2016 Mar 9. [Epub ahead of print] 

Arne Conrad, Petra Feyer, Ulrike Höller, Claudia Hörl, Monika Panzer, Dorothea Riesenbeck, Diana Steinmann, Christof Schäfer, Dirk Vordermark for the DEGRO Quality of Life Group. Patient information in radiation oncology: a German multi-Center cross-sectional study using the EORTC QLQ-INFO26 module. Strahlenther Onkol 2016; 192 (1). 

2015 

Gunther S, Ostheimer C, Specht A, Erl J, Breuninger S, Combs S, Multhoff G. Development of a novel LipHsp70 ELISA for screening of exosomal Hsp70 in the blood of NSCLC patients. Strahlenther Onkol 2015, Suppl 1;191:S72. 

Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW. Erratum: Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd. 2015 Oct;75(10):e3. 

Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M. Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer. 2015 Dec 22;15:997. doi 10.1186/s12885-015-2002-6.

Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, Jordan K, Vordermark D, Landenberger M, Jahn P. PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. Support Care Cancer. 2015 Dec 16. [Epub ahead of print]

Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW. Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1028-1042.

Gunther S*, Ostheimer C*, Stangl S, Specht HM; Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G. Correlation of HSP70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol. 2015 Nov 2;6:556. eCollection 2015. 

Bache M, Münch C, Güttler A, Wichmann H, Theuerkorn K, Emmerich D, Paschke R, Vordermark D. Betulinyl Sulfamates as Anticancer Agents and Radiosensitizers in Human Breast Cancer Cells. Int J Mol Sci. 2015 Nov 3;16(11):26249-62. doi.10.3390/ijms161125953. 

Ostheimer C, Sudmann J. Die junge DEGRO (jDEGRO) - Fortschritt durch Nachwuchs. FORUM. 2015 Oct;30(5):394-396. DOI 10.007/s12321-015-1377-2.

Mauz-Körholz C, Lange T, Hasenclever D, Burkhardt B, Feller AC, Dörffel W, Kluge R, Vordermark D, Körholz D. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr. 2015 Sep 10. [Epub ahead of print]. 

Kessler J, Güttler A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of oxygenation status. Radiother Oncol. 2015 Sep;116(3):381-7. doi: 10.1016/j.radonc.2015.08.007. Epud 2015 Aug 29. 

Wohlleben G, Scherzad A, Güttler A, Vordermark D, Kuger S, Flentje M, Polat B. Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines. Radiat Oncol. 2015 Aug 12;10;167. doi: 10.1186/s13014-015-0473-x.

Schweyen R, Hey J, Seidel J, Wienke A, Paelecke-Habermann Y, Vordermark D, Kuhnt T. Impact of parotid glanbd dose and patient-related factors on radiation damage to dental hard tissues. J Dent Sci. 2015 Jul 7;10;3:263-269.

Jahn F, Riesner A, Jahn P, Sieker F, Vordermark D, Jordan K. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamin-RA in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomittant Cisplatin. Int J Radiat Oncol Biol Phys. 2015 Apr 28. pii: S0360-3016(15)00441-1. doi: 10.1016/k.ijrobp.2015.04.037. [Epub ahead of print].

Bache M, Rot S, Keßler J, Güttler A, Wichman H, Greither T, Wach S, Taubert H, Söling A, Bilkenroth U, Kappler M, Vordermark D. mRNA expression levels of hypoxia-induced stem cell-associated genes in human glioblastoma. Oncol Rep. 2015, 33:3155-3161. doi: 10.3892/or.2015.3932. Epub 2015 Apr 27.

Wedding U, Vordermark D. Lebensqualität alter Patienten mit Krebserkrankungen. Onkologe 2015. DOI 10.1007/s00761-014.2827-7.

Ostheimer C, Bormann C, Fiedler E, Marsch W, Vordermark D. Malignant melanoma brain metastasis: Treatment results and prognostic factors - a single-center retrospective study. Int J Oncol. 2015 Apr 20. doi:10.3892/ijo.2015.2970. [Epub ahead of print].

Steins MB, Vordermark D. Lungenkarzinom. Onkologe 2015. DOI 10.1007/s00761-014-2832-x.

Güttler A, Münch C, Theuerkorn K, Wichmann H, Paschke R, Bache M, Vordermark D. Betulinsäure basierte Carboanhydraseinhibitoren in Kopf-Hals-Tumorzellinien. Exp Strahlenther Klin Strahlenbiol. 2015, 24:146.

Keßler J, Wichmann H, Güttler A, Rot S, Bache M, Vordermark D. Radiosensitivierung von IDH1 R132H-positiven malignen Gliomzellinien unter normoxischen und hypoxischen Bedingungen. Exp Strahlenther Klin Strahlenbiol. 2015, 24:90-94

Bache M, Münch C, Wichmann H, Güttler A, Theuerkorn K, Paschke R, Vordermark D. Betulinylsulfamate in Kombination mit einer Bestrahlung in MDA.MB231-Zellen. Exp Strahlenther Klin Strahlenbiol. 2005, 24:45-46.

Theurkorn K, Güttler A, Thews O, Bache M, Vordermark D. Wirkung des Carboanhydrase IX (CAIX) Inhibitors U104 an humanen Tumorzellen in Abhängigkeit vom O2-Gehalt bzw. pH-Wert. Exp Strahlenther Klin Strahlenbiol. 2015, 24:31-36.

Ostheimer C, Meyer F, Kornhuber C, Reese T, Vordermark D. What does the General and Abdominal Surgeon Need to Know about Radiotherapy? Aspects of Radiotherapy in General and Abdominal Surgery. Zentralbl Chir. 2015 Feb;140(1):83-93. doi: 10.1055/s-0034-1383338. Epub 2015 Feb 27.

Wedding U, Vordermark D, Germer CT, Höffken K. Der "graue Tsunami" in der Onkologie. Onkologe 2015. DOI 10.1007/s00761-014-2823-y.

2014

Kaufmann A, Schmidt H, Ostheimer C, Landenberger M, Vordermark D. Quality of life in very elderly radiotherapy patients: a prospective pilot study using the EORTC QLQ-ELD14 module. Support Care Cancer. 2014 Dec 6. [Epub ahead of print]

Körholz D, Mauz-Körholz C, Vordermark D, Kluge R, Dieckmann K. Increased Relapse Rates in Early Stage Hodgkin Lymphoma (HL) Patients without Radiotherapy: The German Society of Radiooncology (DEGRO) Advises to Treat All Early Stage HL Patients with Radiotherapy. Klin Padiatr. 2014.Nov;226(6-7):307-8. doi: 10.1055/s-0034-1389928. Epub 2014 Nov 28.

Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014 Nov 21;14:858. doi: 10.186/1471-2407-14-858.

Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R, Vordermark D. Betulinic Acid Derivates MVX-207 and B10 for Treatment of Glioblastoma - An in Vitro Study of Cytotoxicity and Radiosensitization. Int J Mol Sci. 2014 Oct;15(11):19777-90. doi: 10.3390/ijms151119777.

Ostheimer C, Hübsch P, Reese T, Vordermark D. Aktuelle strahlentherapeutische Aspekte in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms. J Onkol. 2014; 7:482-489.

Vordermark D. Stereotactic Body Radiation Therapy for Prostate Cancer: The Need to Assess Patient-Reported Outcomes. J Clin Oncol. 2014 Oct 20;32(30):3456. doi 10.1200/JCO.2014.56.2215. Epub 2014 Sep 2.

Wichmann H, Güttler A, Bache M, Taubert H, Rot S, Kessler J, Eckert AW, Kappler M, Vordermark D. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: A comparative study in glioblastoma cells. Strahlenther Onkol 2014 Auf 27 [Epub ahead of print]

Gnanapragassam VS, Bork K, Galuska CE, Galuska SP, Glanz D, Nagasundaram M, Bache M,  Vordermark D, Kohla G, Kannicht C, Schauer C, Horstkorte R. Sialic Acid metabolic engineerin: a potential strategy for the neuroblastoma therapy. PLoS One 2014 Aug 22;9(8):e105403. doi:10.1371/journal.pone0105403. eCollection 2014.

Kantelhardt EJ, Moelle U, Begoinh M, Addissie A, Trocchi P, Yonas B, Hezkiel P, Stang A, Thomssen C, Vordermark D, Gemechu T, Gebrehiwot Y, Wondemagegnehu T, Aynalem A, Mathewos A. Cervical cancer in ethiopia: survival if 1,059 patients who received oncologic therapy. Oncologist. 2014 Jul;19(7):727-34. doi: 10.1634/theoncologist.2013-0326. Epub 2014 Jun 20.

Dumke AK, Pelz T, Vordermark D: Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol. 2014 Mar 31;9(1):90. 

Ostheimer C, Janich M, Hübsch P, Gerlach R, Vordermark D: The treatment of extensive scalp lesions using coplanar and non-coplanar photon IMRT: a single institution experience. Radiat Oncol. 2014 Mar 24;9:82. 

Schlitt A, Jordan K, Vordermark D, Schwamborn JR, Langer T, Thomssen C: Cardiotoxicity and oncological treatments. Dtsch Arztebl Int. 2014 Mar 7;111(10):161-8. 

Wichmann H, Güttler A, Bache M, Taubert H, Vetter M, Würl P, Holzhausen HJ, Eckert AW, Kappler M, Vordermark D: Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. Strahlenther Onkol. 2014 Apr 9. [Epub ahead of print]

Wichman H, Güttler A, Bache M, Taubert H, Rot S, Kessler J, Eckert A, Kappler M und Vordermark D. EGFR and Her2: Comparing antibody and siRNA targeting in glioblastoma cells. Exp Strahlenther Klin Strahlenbiol. 2014, 23:26-30.

Bache M, Rot S, Keßler J, Güttler A, Wichmann H, Greither T, Taubert H, Söling A, Bilkenroth U, Kappler M und Vordermark D. mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Exp Strahlenther Klin Strahlenbiol. 2014, 23:70-4.

Theuerkorn A, Güttler A, Thews O, Bache M und Vordermark D. Targeting von Carboanhydrase IX (CAIX) in Kombination mit Strahlentherapie humaner Tumorzellen. Exp Strahlenther Klin Strahlenbiol. 2014, 23:41-5.

Hein A, Bernhardt S, Passi S, Zschornak M, Paschke R, Bache M und Vordermark D. Molekulare und strahlenbiologische Untersuchungen der Bedeutung von Abkömmlingen der Betulinsäure in Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2014, 23:12-6.

Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Oncol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.

2013

Wichmann H, Güttler A, Kessler J, Rot  S, Bache M, Vordermark D, Kappler M und Eckert A. Bedeutung von EGFR, seiner Spleißvarianten und Her2 in verschiedenen Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2013, 22:48-52.

Ostheimer C, Bache M, Hahnel A, Kotzsch M und Vordermark D. Kombinierte Analyse von Osteopontin (OPN) und VEGF, PAI, UPA und UPA-R als potentielle Kandidaten zur Etablierung eines prognostisch-prädiktiven Marker-Panels in der Radiotherapie von Bronchialkarzinomen: erste Daten. Exp Strahlenther Klin Strahlenbiol. 2013, 22:30-5.

Keßler J, Güttler A, Wichmann H, Bache M und Vordermark D. Überexpression von IDH1 R132H und die Strahlenresistenz maligner Gliome. Exp Strahlenther Klin Strahlenbiol. 2013, 22:72-6.

Kappler M, Rot S, Wichmann H, Güttler A, Kessler J, Taubert H, Bache M, Vordermark D und Eckert A. Rolle von HIF1α im normoxischen und hypoxischen Metabolismus. Exp Strahlenther Klin Strahlenbiol. 2013, 22:111-4.

Güttler A, Wichmann H, Keßler J, Ostheimer C, Kappler M, Vordermark D und Bache M. Expressionsanalyse und Lokalisation von Osteopontin und seinen Spleißvarianten in Mamma- und Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2013, 22:24-8.

Knäusl B, Lütgendorf-Cauciq C, Hopfgartner J, Dieckmann K, Kurch L, Pelz T, Pötter R, Georg D. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol. 2013, 189:54-61.

Bache M, Bernhardt S, Hein A, Passin S, Zschornak M, Paschke R und Vordermark D. Betulinsäurederivate für die Therapie von Glioblastomen in vitro. Exp Strahlenther Klin Strahlenbiol. 2013, 22:43-7.

Becker JC, Assaf C, Vordermark D, Reske SN, Hense J, Dettenborn T, Seitz O, Grabbe S. Brief S2k guidelines--Merkel cell carcinoma. J Dtsch Dermatol Ges. 2013 Jun;11 Suppl 3:29-36, 31-8.

Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A; German Societies of General and Visceral Surgery; Endocrinology; Nuclear Medicine; Pathology; Radiooncology; Oncological Hematology; and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013 Mar;398(3):347-75.

Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, Vordermark D, Bache M. Osteopontin and splice variant expression level in human malignant glioma: Radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 2013 Jul 25.

Müller K, Gnekow A, Falkenstein F, Scheiderbauer J, Zwiener I, Pietsch T, Warmuth-Metz M, Voges J, Nikkhah G, Flentje M, Combs SE, Vordermark D, Kocher M, Kortmann RD. Radiotherapy in pediatric pilocytic astrocytomas : A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol. 2013 Aug;189(8):647-655.

Müller K, Schlamann A, Seidel C, Warmuth-Metz M, Christiansen H, Vordermark D, Kortmann RD, Kramm CM, von Bueren AO. Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma : A compassionate use treatment. Strahlenther Onkol. 2013 Aug;189(8):693-696.

Oskan F, Kornhuber C, Krause G, Vordermark D.
Simultaneous stereotactiv radiation therapy of a primary non-small cell lung cancer and synchrnous carcinoma in situ in a medically inoperabable patient: case report.
Radiation Oncology 2013,8:213.
Ostheimer C, Vordermark D: (2013) Osteopontin – an indicator of tumor hypoxia and treatment resistance. In: Vordermark D (Hrsg.), Hypoxia: Causes, Types and Management (255-318). New York: Nova Publishers.

Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D. S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. J Dtsch Dermatol Ges. 2013 Jun;11(6):563-602.

Lütgendorf-Cauciq C, Fortina I, Gallop-Evans E, Claude L, Lindh J, Pelz T, Knäusl B, Georg D, Pötter R, Dieckmann K; EuroNet-PHL RT-Group. Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study. Strahlenther Onkol. 2012, 188:1025-1030.

Steinbach J, Vordermark D, Gutzmer R. ZNS-Metastasen - eine interdisziplinäre Herausforderung.Onkologie. 2013;36 Suppl 4:2-6.

Steinmann D, Vordermark D, Geinitz H, Aschoff R, Bayerl A, Gerstein J, Hipp M, van Oorschot B, Wypior HJ, Schäfer C: (2013) Proxy assessment of patients before and after radiotherapy for brain metastases : Results of a prospective study using the DEGRO brain module. STRAHLENTHER ONKOL 189(1):47-53. 

Vordermark D (Hrsg.). (2013). Hypoxia: Causes, Types and Management. New York: Nova Publishers.

Vordermark D. Radiation therapy for metastatic non-small-cell lung cancer: when to bring in palliative care? J Clin Oncol. 2013 Jul 20;31(21):2758-9.

Vordermark D. Beeinflusst die Einnahme von Statinen das Behandlungsergebnis der Strahlentherapie beim Prostatakarzinom? Urologe A. 2013 Feb;52(2):264. 

2012

Greither T, Koser F, Kappler M, Bache M, Lautenschläger C, Göbel S, Holzhausen HJ, Wach S, Würl P, Taubert H. (2012) Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients. BMC Cancer. 2012, 12:272.

Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D, Bache M: (2012) Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC CANCER. 2012, 12:131.

Hahnel A, Giebler M, Wichmann H, Kappler M, Vordermark D, Bache M: (2012) Molekulare und strahlenbiologische Effekte der Inhibierung der OPN-Spleißvarianten in humanen Glioblastomen. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:54-8.

Hey J, Seidel J, Schweyen R, Paelecke-Habermann Y, Vordermark D, Gernhardt C, Kuhnt T: (2012) The influence of parotid gland sparing on radiation damages of dental hard tissues. CLIN ORAL INVESTIG. 2012 Oct 5.

Jahn P, Lakowa N, Vordermark D, Stoll O, Landenberger M: (2012) InterACTIV – An Exploratory Study of the Utilization of a Game Console to Promote Physical Activation of Hospitalized Adult Cancer Patients. ONCOL NURS FORUM. 2012, 39:E84-90.

Kappler M, Taubert H, Schubert J, Vordermark D, Eckert AW: (2012) The real face of HIF1α in the tumor process. CELL CYCLE. 2012, 11(21):3932-6.

Kappler M, Wichmann H, Rot S, Hüttelmaier S, Taubert H, Schubert J, Bache M, Vordermark D, Eckert AW: (2012) Expressionsanalyse in der Weichteilsarkomzelllinie SKLMS-1 nach EGF-Stimulation. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:119-122.

Keßler J, Hahnel A, Rot S, Bache M, Vordermark D: (2012) Einfluss von IDH1 auf HIF-1α und die Strahlenresistenz maligner Gliome. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:59-63.

Kockar F, Yildrim H, Sagkan RI, Hagemann C, Soysal Y, Anacker J, Hamza AA, Vordermark D, Flentje M, Said HM: (2012) Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. WORLD J CLIN ONCOL. 2012, 3:82-91.

Oskan F, Vordermark D: (2012) Quality of life after prophylactic cranial irradiation in locally advanced non-small-cell lung cancer. STRAHLENTHER ONKOL. 2012, 188:363-4.

Ostheimer C, Vordermark D: (2012) Osteopontin, a marker of hypoxic radiation resistance?  – state of the art, own experiences and critical review of the literature. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:43-9

Said HM, Polat B, Stein S, Guckenberger M, Hagemann C, Staab A, Katzer A, Anacker J, Flentje M, Vordermark D: (2012) Inhibition of N-Myc down regulated gene 1 in in vitro cultured human glioblastoma cells. WORLD J CLIN ONCOL 3:104-10.

Schweyen R, Hey J, Fränzel W, Vordermark D, Hildebrandt G, Kuhnt T: (2012) Radiation-related caries: etiology and possible preventive strategies: What should the radiotherapist know? STRAHLENTHER ONKOL. 2012, 188:21-8.

Steinmann D, Paelecke-Habermann Y, Geintiz H, Aschoff R, Bayerl A, Bölling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Mueller AR, Schaefer C, Schleicher U, Sehlen S, Theodorou M, Wypior HJ, Zehentmayr F, Oorschot B van, Vordermark D: (2012) Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC CANCER. 2012, 12:283.

Vordermark D: (2012) Editorial comment. J UROL. 2012, 187:123.

2011

Bache M, Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R, Kaluđerović GN, Kommera H, Taubert H, Vordermark D: (2011) Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. RADIAT ONCOL 6:111.

Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschläger C, Holzhausen HJ, Wach S, Eckert AW, Taubert H: (2011) Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. INT J CANCER 2011 Mar 31 [Epub ahead of print]

Gutzmer R, Jäger E, Vordermark D: (2011) Adjuvante Therapieansätze in der Onkologie: Eine kritische Nutzen-Risiko-Abwägung. ONKOLOGIE 34(suppl 2):10-12.

Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, Gernhardt CR, Kuhnt T: (2011) Parotid gland-recovery after radiotherapy in the head and neck region: 36 months follow-up of a prospective clinical study.RADIAT ONCOL 6:125.

Kappler M, Hanke S, Rot S, Wichmann H, Taubert H, Eckert A, Bache M, Vordermark D: (2011) Rolle des Insulin/EGFR-PI3K/AKT-Survivin-Signalwegs in Tumorzellen – Identifizierung einer Zelllinie mit induzierbarem / intaktem Pathway. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:39-43.

Keschke CB, Kappler M, Taubert H, Bache M, Schubert J, Vordermark D, Eckert AW: (2011) Survivinexpression als prognostischer Faktor für Patienten mit Munhöhlenkarzinom. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:51-5.

Kotzsch M, Magdolen V, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Eckert AW, Luther T, Baretton G, Würl P, Taubert H: (2011) Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC CANCER 11:273.

Ostheimer C, Wichmann H, Kappler M, Bache M, Kotzsch M, Vordermark D: (2011) Der Plasma-Hypoxiemarker Osteopontin als Prognosefaktor für die Radiotherapie des Bronchialkarzinoms: erste Survival-Analyse. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:217-22.

Rot S, Taubert H, Bache M, Greither T, Wurl P, Eckert AW, Schubert J, Vordermark D, Kappler M: (2011) A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. BMC CANCER11:429.

Rot S, Taubert H, Keßler J, Bache M, Eckert A, Vordermark D, Kappler M: (2011) Inhibierung des Stammzellmarkers GPR49 in Glioblastom- und Weichteilsarkomzelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:45-9.

Staab A, Fleischer M, Loeffler J, Said HM, Katzer A, Plathow C, Einsele H, Flentje M, Vordermark D: (2011) Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. STRAHLENTHER ONKOL, 187:252-9.

Steinmann D, Bremer M, Vordermark D (2011): Verzicht auf Ganzhirnbestrahlung nach Radiochirurgie ist vertretbar. IM FOCUS ONKOLOGIE, 5:22-3.

Vordermark D: (2011) Ten years of progress in radiation oncology. BMC CANCER 11(1):503.

Vordermark D: (2011) Beeinflußt die Einnahme von Statinen die Tumorkontrolle nach Strahlentherapie eines Prostatakarzinoms? STRAHLENTHER ONKOL, 187:218-9.

Vordermark D: (2011) Dosis-Volumen-Histogramme für die Strahlentherapie: wichtige Informationen für die Therapieplanung. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:183-4.

Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R, Taubert H, Vordermark D, Bache M: (2011) Effekte von Betulinsäure und Bestrahlung in malignen Gliom-Zelllinien unter normoxischen und hypoxischen Bedingungen. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:59-63.

 

2010

Bache M, Kappler M, Rot S, Wichmann H, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC CANCER, 10:132.

Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M: (2010) Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. RADIAT ONCOL, 5:82.

Hahnel A, Greither T, Würl P, Vordermark D, Taubert H, Bache M: (2010) Prognostische Relevanz der Osteopontin-Spleißvarianten bei Weichteilsarkompatienten mit postoperativer Radiochemo- oder Chemotherapie. EXP STRAHLENTHER KLIN STRAHLENBIOL, 19:15-19.

Janssen S, Meyer A, Vordermark D, Steinmann D: (2010) Radiotherapy and internet – what can patients expect? Homepage analysis of German radiotherapy institutions. STRAHLENTHER ONKOL, 186 (12):700-4.

Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D: (2010) HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC CANCER, 10(1):605.

Kessler J, Bache M, Vordermark D: (2010) Einfluß einer HIF-1α-Inhibierung durch siRNA oder Chetomin auf die Strahlenresistenz maligner Gliom-Zelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL ,19:5-9.

Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J: (2010) Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. ANN ONCOL, 21(11):2284-9.

Kuhnt T, Janich M.: (2010) Prinzipien der Strahlentherapie bei malignen orbitalen und periorbitalen Raumforderungen. HNO, 58(1):15-23.

Machann W, Beer M, Breunig M, Stoerk S, Angermann C, Seufert I, Schwab F, Koelbl O, Flentje M, Vordermark D: (2010) Cardiac MRI findings in 20-year survivors of mediastinal radiotherapy for Hodgkin´s disease. INT J RADIAT ONCOL BIOL PHYS, Epub 20 April 2010

Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in Paediatric Hodgkin`s Lymphoma: Results of the GPOH-HD-2002 study. J CLIN ONCOL, 28(23):3680-6.

Ostheimer C, Wichmann H, Hahnel A, Reese T, Kappler M, Bache M, Kotzsch M, Vordermark D: (2010) Evaluation von Osteopontin und alternativen Plasmamarkern der hypoxischen Strahlenresistenz bei Patienten mit Bronchialkarzinom. EXP STRAHLENTHER KLIN STRAHLENBIOL, 19:31-36.

Said HM, Supuran CT, Hagemann C, Staab A, Polat B, Katzer A, Scozzafava A, Anacker J, Flentje M, Vordermark D. (2010) Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des, 16 (29):3288-99.

Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: (2010) Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. BR J CANCER, 102(4):731-7. 

Taubert H, Heidenreich C, Holzhausen HJ, Schulz A, Bache M, Kappler M, Eckert AW, Würl P, Melcher I, Hauptmann K, Hauptmann S, Schaser KD: (2010) Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC CANCER, 10:65.

Vordermark D, Pelz T, Sieker F: (2010) Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms. ONKOLOGE, 16(7):695-700.

Vordermark D: (2010) Hypoxia-specific targets in cancer therapy: role of splice variants. BMC MED, 8:45.

Vordermark D: (2010) Patient information and decision aids in oncology: need for communication between patients and physicians. J CLIN ONCOL, 28(29):e567.

Vordermark D: (2010) Early palliative care for patients with metastastic non-small-cell lung cancer. N ENGL J MED, 363 (23):2264.

Vordermark D: (2010) Stereotaktische Radiotherapie oder Wedge-Resektion bei NSCLC im Stadium I? Ein retrospektiver Vergleich. STRAHLENTHER ONKOL, 186(11), 644-6.

Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rödel C: (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. INT J RADIAT ONCOL BIOL PHYS, 78(2):472-8.

 

2009

Adler J, Paelecke-Habermann Y, Jahn P, Landenberger M, Leplow B, Vordermark D.: (2009) Patient information in radiation oncology: a cross-sectional pilot study using the EORTC QLQ-INFO26 module. RADIAT ONCOL, 4:40.

Bekes K, Francke U, Schaller HG, Kuhnt T, Gerlach R, Vordermark D, Gernhardt CR.: (2009) The influence of different irradiation doses and desensitizer application on demineralization of human dentin. ORAL ONCOL, 45(9): e80-4.

Bratengeier K, Meyer J, Schwab F, Vordermark D, Flentje M.:(2009) Steep dose gradients for simultaneous integrated boost IMRT. Z MED PHYS, 19:129-35. 

Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabilic R, Vanselow B, Blinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). EUR ARCH OTORHINOLARYNGOL 266(8):1291-300.

Eckert AW, Lautner MH, Schütze A, Bolte K, Bache M, Kappler M, Schubert J, Taubert H, Bilkenroth U.: (2009) Co-expression of HIF1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J ORAL PATHOL MED, Epub 25 Sep 2009.

Fränzel W, Gerlach R. (2009) The irradiation of human dental tissue by X-rays and electrons – a nanoindenter study. Z MED PHYS, 19:5-10.

Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, Kühnel S, Meyer C, Rapp UR, Kämmerer U, Vordermark D, Flentje M, Roosen K, Vince GH.: (2009) RAF expression in human astrocytic tumors. INT J MOL MED, 23(1):17-31.

Hahnel A, Wichmann H, Kappler M, Vordermark D, Taubert H, Bache M.: (2009) Einfluss des Osteopontin auf die Strahlenresistenz der humanen Mammakarzinomzelllinie MDA-MB-231. EXP STRAHLENTHER KLIN STRAHLENBIOL 18:39-43.

Hey J., Setz J., Gerlach R., Janich M., Sehlleier S., Schaller H. G., Gernhardt C. R., Kuhnt T.: (2009) Parotid-gland-sparing 3D conformal radiotherapy in patients with bilateral radiotherapy of the head and neck region – Results in clinical practice. ORAL ONCOL, 45(2):e11-7.

Hey J, Setz J, Gerlach R, Vordermark D, Gernhardt CR, Kuhnt T.:(2009) Effect of cisplatin on parotid gland function in concomitant radiochemotherapy. INT J RADIAT ONCOL BIOL PHYS, 75(5):1475-80.

Keßler J, Rot S, Kappler M, Vordermark D, Taubert H, Bache M.: (2009) Bestrahlung und Survivin-spezifische siRNA in mesenchymalen Stammzellen (MSC) und Weichteilsarkomen (WTS). EXP STRAHLENTHER KLIN STRAHLENBIOL 18: 93-97.

Kuhnt T, Klockenbrink U, Pelz T, Wienke A, Janich M, Sandner A, Lautermann J, Vordermark D, Schubert J.: (2009) Postoperative radiotherapy versus concurrent radiochemotherapy for locally advanced squamous cell carcinoma of the oral cavity and the oropharynx. NEW ARMENIAN MED J, 3: 11-21.

Kuhnt T, Friese M, Vordermark D.: Cardiac toxicity after radiotherapy for breast cancer: current concepts of associated risk and strategies of dose reduction. In: Ford TD (ed.) New Cancer Research Developments, Nova Science Publishers, New York, 2009.

Said HM, Stein S, Hagemann C, Polat B, Staab A, Anacker J, Schoemig B, Theobald M, Flentje M, Vordermark D.: (2009) Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. ONCOL REP, 21(1):237-46.

Said HM, Polat B, Hagemann C, Anacker J, Flentje M, Vordermark D.:(2009) Absence of GAPDH regulation in tumour cells of different origin under hypoxic conditions in vitro. BMC RES NOTES 2:8.

Sehlen S, Vordermark D, Schafer C, Herschbach P, Bayerl A, Pigorsch S, Rittweger J, Domin C, Bolling T, Wypior HJ, Zehentmayr F, Schulze W, Geinitz H.: (2009) Job stress and job satisfaction of physicians, radiographers, nurses and physicists working in radiotherapy: a multicenter analysis by the DEGRO Quality of Life Work Group. RADIAT ONCOL, 4:6.

Steinmann D, Schäfer C, van Oorschot B, Wypior HJ, Bruns F, Bölling T, Sehlen S, Hagg J, Bayerl A, Geinitz H, Hipp M, Vordermark D: Effects of radiotherapy for brain metastases on quality of life (QoL): prospective pilot study of DEGRO QoL Working Party. STRAHLENTHER ONKOL, 185(3):190-7.

Stromiedel M, Bache M, Vordermark D, Rot S, Wichmann H, Taubert H, Kappler M.: (2009) Untersuchung der Effekte des EGFR-Targeting mittels siRNA- bzw. spezifischer Antikörper in der Weichteilsarkomzelllinie SKLMS-1. EXP STRAHLENTHER KLIN STRAHLENBIOL 18:87-91.

Vordermark D, Noe M, Markert K, Wulf J, Müller G, Bratengeier K, Beckmann G, Baier F, Guckenberger M, Schiefelbein F, Schön G, Flentje M, Baier K.:(2009) Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: importance of baseline symptoms and of prostate-V150. RADIOTHER ONCOL , 91 (2):217-24.

Vordermark D.: (2009) Cause-specific colostomy rates after chemoradiotherapy for anal carcinoma: cancer-related vs. treatment-related colostomy. J CLIN ONCOL, 27(18):3064.

Wichmann H, Bache M, Vordermark D, Taubert H, Kappler M.: (2009) Targeting des potentiellen Hypoxiemarkers Osteopontin in humanen Sarkom-Zelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL, 18:15-9.

 

2008

Bache M., Kappler M., Said H. M., Staab A., Vordermark D.: (2008) Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. CURR MED CHEM, 15(4):322-338.

Dellas K., Bache M., Pigorsch S. U., Taubert H., Kappler M., Holzapfel D., Zorn E., Holzhausen H. J., Haensgen G.: (2008) Prognostic impact of HIF-1a expression in patients with definitive radiotherapy for cervical cancer. STRAHLENTHER ONKOL, 184(3):169-174.

Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Roedel C, Zuehlke H, Hinke A.: (2008) Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer. Mature results of a phase II trial. STRAHLENTHER ONKOL, 184(9)450-6.

Guckenberger M., Baier K., Richter A., Vordermark D., Flentje M..:(2008) Does intensity-modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only? RADIAT ONCOL, 3:3.

Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Pater R, Kämmerer U, Vordermark D, Roosen K, Vince GH.: (2008) Expression analysis of the autosomal recessive primary microcephaly genes MCPD1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. ONCOL REP, 20(2):301-8. 

Hänsgen G, Grund D, Schneider A, Marnitz S, Köhler C.: (2008) Die Therapie von Frauen mit Endometriumkarzinom. ONKOLOGE 14(6):633-44.

Kappler M., Taubert H., Holzhausen H.-J., Reddemann R., Rot S., Becker A., Kuhnt T., Dellas K., Dunst J., Vordermark D., Hänsgen G., Bache M.: (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer: prognostic role and correlation with tumor markers and tumor oxygenation parameters. STRAHLENTHER ONKOL, 184(8):393-9.

Rödel C., Arnold D., Hipp M., Liersch T., Dellas K., Iesalnieks I., Hermann R.M., Lordick F., Hinke A., Hohenberger W., Sauer R.: (2008) Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. INT J RADIAT ONCOL, 70(4):994-1001.

Said HM, Polat B, Staab A, Hagemann C, Stein S, Flentje M, Theobald M, Katzer A, Vordermark D.: (2008) Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. ONCOL REP, 20(2):413-9.

Semrau R., Hansemann K., Adam M., Andratschke N., Brunner T., Heinzelmann F., Hildebrandt G., Vordermark D., Zips D.: (2008) Quality of Training in Radiation Oncology in Germany – Results of a 2006 Survey by “YoungDEGRO”. STRAHLENTHER ONKOL, 184(5):239-244. 

Strauss H.G., Haensgen G., Dunst J., Hayward C.R., Burger H.U., Scherhag A., Koelbl H.: (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. INT J GYNECOL CANCER, 18(3):515-24. 

Taubert H, Bartel F, Greither T, Bache M, Kappler M, Köhler T, Böhnke A, Lautenschläger C, Schmidt H, Holzhausen HJ, Hauptmann S, Würl P. : (2008) Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas. MOL CANCER RES, 6(10):1575-81.

Vordermark D.: (2008) Potential and limitations of intensity-modulated radiotherapy in anal cancer. J CLIN ONCOL, 26(4):688.

Vordermark D.: (2008) Temporal changes in quality of life (QoL) of primary brain tumor patients: raw QoL data from randomized trial as reference for future studies. J CLIN ONCOL, 26(12):2061-2062.

Vordermark D.: (2008) Skin-sparing intensity-modulated radiotherapy of the breast. J CLIN ONCOL, 26(19):3292.

Vordermark D.: (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N ENGL J MED 359(2):201.

Vordermark D, Guckenberger M, Baier K, Markert K. (2008) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102). INT J RADIAT ONCOL BIOL PHYS 71(1):316-317.

 

2007

Capalbo G., Rödel C., Stauber R.H., Knauer S.K., Bache M., Kappler M., Rödel F.: (2007) The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. STRAHLENTHER ONKOL, 183(11): 593-599.

Kappler M., Rot S., Taubert H., Greither T., Bartel F., Dellas K., Hänsgen G., Trott K.R., Bache M.: (2007) The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. CANCER GENE THER, 14(12):994-1001.

Kuhnt T., Friese M., Janich M., Gerlach R., Pelz T., Haensgen G.: (2007) Possibility of radiotherapy-associated cardiovascular side effects in breast cancer patients by modern radiotherapy techniques. Breast J, 13(1): 103-105.

Kuhnt T., Pelz T., Qu X., Hänsgen G., Dunst J., Gellerich F.N.: (2007) Mitochondrial OXPHOS Functions in R1H Rhabdomyosarcoma and Skeletal Muscles of the Rat. NEUROCHEM RES, 32(6):973-980.

Müller A.C., Diestelhorst A., Kuhnt T., Kühn R., Fornara P., Scholz H.J., Dunst J., Zietman A.L.: (2007) Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. STRAHLENTHER ONKOL, 183(4): 177-183.

Rödel C., Liersch T., Hermann R.M., Arnold D., Reese T., Hipp M., Fürst A., Schwella N., Bieker M., Hellmich G., Ewald H., Haier J., Lordick F., Flentje M., Sülberg H., Hohenberger W., Sauer R.: (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J CLIN ONCOL, 25(1): 110-117.

Said H.M., Hagemann C., Staab A., Stojic J., Kühnel S., Vince G.H., Flentje M., Roosen K., Vordermark D.: (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. RADIOTHER ONCOL, 83(3): 398-405.

Said H.M., Hagemann C., Stojic J., Schoemig B., Vince G.H., Flentje M., Roosen K., Vordermark D.: (2007) GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC MOL BIOL, 8: 55.

Said H.M., Staab A., Hagemann C., Vince G.H., Katzer A., Flentje M., Vordermark D.: (2007) Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J NEURO-ONCOL, 81(1): 27-38.

Staab A., Loeffler J., Said H.M., Diehlmann D., Katzer A., Beyer M., Fleischer M., Schwab F., Baier K., Einsele H., Flentje M., Vordermark D.: (2007) Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC CANCER, 7: 213.  

Staab A., Löffler J., Said H.M., Katzer A., Beyer M., Polat B., Einsele H., Flentje M., Vordermark D.: (2007) Modulation of glucose metabolism inhibits hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). STRAHLENTHER ONKOL, 183(7): 366-373.  

Taubert H., Würl P., Greither T., Kappler M., Bache M., Bartel F., Kehlen A., Lautenschläger C., Harris L.C., Kaushal D., Füssel S., Meye A., Böhnke A., Schmidt H., Holzhausen H.J., Hauptmann S.: (2007) Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. ONCOGENE, 26(50):7170-7174.  

Vordermark D.: (2007) Prophylactic radiotherapy for glioblastoma in the elderly. NEW ENGL J MED, 357(2): 195-196.  

Vordermark D.: (2007) Avoiding bias in the prospective evaluation of patients with brain metastases. J CLIN ONCOL, 25(25): 4023.  

Vordermark D., Lackenbauer A., Wulf J., Guckenberger M., Flentje M.: (2007) Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. ONCOL REP, 18(5): 1335-1339.  

Vordermark D., Marold D., Wirth S., Keilholz L., Pfändner K., Schimpke T., Thiel H.J., Willner J., Ziegler K., Guckenberger M., Flentje M.: (2007) Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998-2000. STRAHLENTHER ONKOL, 183(6): 314-320.  

Wuttig D., Kunze D., Fuessel S., Toma M., Stade J., Kotzsch M., Kappler M., Taubert H., Schwenzer B., Baretton G., Hakenberg O.W., Meye A., Wirth M.P.: (2007) Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? INT J ONCOL, 30(6): 1317-24

 

2006

Bache M., Holzapfel D., Kappler M., Holzhausen H.J., Taubert H., Dunst J., Hänsgen G.: (2006) Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. GYNECOL ONCOL, 104(1):139-144.

Bache M., Reddemann R., Said H.M., Holzhausen H.J., Taubert H., Becker A., Kuhnt T., Hänsgen G., Dunst J., Vordermark D.: (2006) Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. INT J RADIAT ONCOL, 66(5):1481-1487.

Fränzel W., Gerlach R., Hein H.J., Schaller H.G.: (2006) Effect of tumor therapeutic irradiation on the mechanical properties of teeth tissue. Z MED PHYS, 16(2): 148-154.

Guckenberger M., Pohl F., Baier K., Meyer J., Koelbl O., Flentje M., Vordermark D.: (2006) Influence of rectum delineation (rectal volume vs. rectal wall) on IMRT treatment planning of the prostate. STRAHLENTHER ONKOL, 182(12): 721-726.

Kuhnt T., Becker A., Bloching M., Schubert J., Klautke G., Fietkau R., Dunst J.: (2006) Phase II Trial of a Simultaneous Radiochemotherapy with Cisplatinum and Paclitaxel in Combination with Hyperfractionated-Accelerated Radiotherapy in Locally Advanced Head and Neck Tumors. MED ONCOL, 23(3): 325-334.

Kuhnt T., Janich M., Götz U., Gerlach R., Chiricuta I.C., Hänsgen G.: (2006) Presentation of a 3D Conformal Radiotherapy Technique for Head-and-Neck Tumors Resulting in Substantial Protection of the Parotid Glands. STRAHLENTHER ONKOL, 182(6): 325-330.

Taubert H., Greither T., Kaushal D., Würl P., Bache M., Bartel F., Kehlen A., Lautenschläger C., Harris L., Kraemer K., Meye A., Kappler M., Schmidt H., Holzhausen H.J., Hauptmann S.: (2006) Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma. ONCOGENE, 26(7):1098-1100.

Vordermark D., Ruprecht K., Rieckmann P., Roggendorf W., Vince G.H., Warmuth-Metz M., Kölbl O., Flentje M.: (2006) Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC CANCER, 6: 247.

Vordermark D., Said H.M., Katzer A., Kuhnt T., Hansgen G., Dunst J., Flentje M., Bache M.: (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC CANCER, 6(1): 207.

Vordermark D., Seufert I., Schwab F., Kölbl O., Kung M., Angermann C., Flentje M.: (2006) 3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures. Radiat Oncol, 1: 10.

Vordermark D., Wulf J., Markert K., Baier K., Kölbl O., Beckmann G., Bratengeier K., Noe M., Schön G., Flentje M.: (2006) 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. ACTA ONCOL, 45(6): 708-716.

 

Universitätsklinik  und Poliklinik für Strahlentherapie

Leitung: 
Prof. Dr. med. Dirk Vordermark
 
Sekretariat: 
Frau Stephanie Fechner

Postanschrift: 
Universitätsklinikum Halle (Saale)
Klinik und Poliklinik für Strahlentherapie
Ernst-Grube-Str. 40
06120 Halle (Saale)

Telefon: 
(0345) 557 4310 

Telefax: 
(0345) 557 4333

E-Mail:
Strahlentherapie@uk-halle.de